Answers are grounded in this paper and cite their sources.
Review reveals advances in sustained-release transdermal NSAID systems for chronic musculoskeletal pain management, suggesting improved patient outcomes.
Musculoskeletal pain associated with conditions such as arthritis, muscle strain, and sports injuries represents a major cause of disability worldwide and is commonly managed using non-steroidal anti-inflammatory drugs (NSAIDs). However, long-term oral administration of NSAIDs is frequently limited by gastrointestinal irritation, cardiovascular risks, and fluctuating plasma drug levels. Sustained-release transdermal drug delivery systems (TDDS) have emerged as a promising alternative by providing controlled drug release through the skin, bypassing hepatic first-pass metabolism and improving patient compliance. This review summarizes recent advances in sustained-release transdermal NSAID systems for musculoskeletal pain management, with emphasis on formulation design strategies, polymer selection, the role of pressure-sensitive adhesives (PSAs), and in-vitro evaluation methodologies. Key aspects such as matrix and drug-in-adhesive patch designs, polymeric matrices, permeation enhancement approaches, and mechanical performance parameters are discussed. In-vitro and ex-vivo studies demonstrate that optimized transdermal patches can maintain therapeutic drug levels for up to 24 hours, offering continuous analgesic and anti-inflammatory effects while reducing dosing frequency. Clinically, transdermal NSAID delivery provides improved tolerability, reduced gastrointestinal exposure, and enhanced patient adherence, particularly in chronic conditions requiring prolonged therapy. Although challenges related to stability, large-scale manufacturing, and regulatory acceptance persist, ongoing innovations in polymer science and formulation technology are expected to accelerate clinical translation. Sustained-release NSAID transdermal systems therefore represent a patient-friendly and effective alternative to conventional oral therapy for long-term musculoskeletal pain management.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: